Get started
Author

Petr Chizhov

Observed name: Petr A. Chizhov
Observed institution: Yaroslavl State Medical Academy
ORCID: 0000-0001-7969-6538
Observed ORCID: 0000-0001-7969-6538
OpenAlex ID: A5112450908
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
2019 · Kausik K Ray, Helen M Colhoun, et al. · The Lancet Diabetes & Endocrinology · 337
PDF
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
2021 · Gregory G. Schwartz, Michael Szarek, et al. · Journal of the American College of Cardiology · 161
PDF
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab
2022 · Emil Hagström, P. Gabriel Steg, et al. · Circulation · 123
PDF
Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment
2021 · Gregory G. Schwartz, Michael Szarek, et al. · Diabetes Care · 40
PDF
Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES
2025 · P. Gabriel Steg, Michael Szarek, et al. · Circulation · 31
PDF
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation
2024 · Shaun G Goodman, Philippe Gabriel Steg, et al. · European Heart Journal - Cardiovascular Pharmacotherapy · 28
PDF
Markers of myocardial stress, fibrosis and inflammation in patients with chronic heart failure of different phenotypes and their relationship with echocardiography parameters
2026 · Darya A. Korsakova, Petr A. Chizhov, et al. · I P Pavlov Russian Medical Biological Herald
Works count: 7
Citation count: 720
H-index: 6
I10-index: 6
Year
Topic
Type